Characteristics and clinical significance of serum soluble programmed cell death receptor-1/ligand-1 and interferon-γ expression in patients with acute coronary syndrome

doi:10.3877/cma.j.issn.2095-9133.2024.01.003

Abstract

Abstract:

Objective

To investigate the expression characteristics and clinical significance of serum sPD-1/L1 and interferon-γ expression in patients with acute coronary syndrome.

Methods

This study retrospectively included 73 patients admitted to the emergency department of Beijing Electric Power Hospital from November 2020 to October 2022. All patients were divided into a control group and a coronary heart disease group (divided into chronic coronary disease group and acute coronary syndrome group). 32 patients in the acute coronary syndrome group, including 19 males and 13 females; Age range from 54 to 84 years old, with an average of (69.09±14.97) years old. There are 21 patients in the chronic coronary disease group, including 8 males and 13 females; Age range from 65 to 83 years old, with an average of (74.24±8.60) years old. 20 cases in the control group, including 13 males and 7 females; Age range from 58 to 73 years old, with an average of (65.70±7.39) years old. Enzyme linked immunosorbent assay (ELISA) was used to detect serum sPD-1, sPD-L1, and IFN in three groups of patients- γ Horizontal.

Results

The comparative analysis of serum immune markers among the three groups showed that there were significant differences in the levels of IL-18, IFN-γThe comparative analysis of serum immune markers among the three groups showed that there were sigisease group were significantly higher than those in the control group (P<0.01), and the expression levels of IFN-an those in the control group ( showed that there were significant differences in the levels of IL-18, IFN-ol group (P<0.05). The expression of L1 in the ACS group and the chronic coronary disease group was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). Pearson correlation analysis showed that serum IFN-p was significantly higher thorrelated with sPD-1 (r=0.922, P<0.01) and L1 (r=0.922, P<0.01) in the ACS group.

Conclusion

There is a certain relationship between sPD-1/L1 and IFN-N-p was significantly higher than that in the control group, and the difference was statistically significssion of sPD-1/L1, which may play an important role in the immunoregulation of ACS.

Key words: Acute coronary syndrome, Soluble programmed cell death Receptor-1, Soluble programmed cell death ligand-1, Interferon-a

Hongxia Niu, Yueran Mao, Qiqi Chen, Junyue Xu, Jing Dong, Zhen Wang, Yanna Yang, Ming Zhang. Characteristics and clinical significance of serum soluble programmed cell death receptor-1/ligand-1 and interferon-γ expression in patients with acute coronary syndrome[J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2024, 10(01): 10-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9133.2024.01.003

https://zhwsyjdzzz.cma-cmc.com.cn/EN/Y2024/V10/I01/10

Figures/Tables 2

References 17

[1]	Fujisue K, Yamamoto E, Sueta D, et al. Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome[J]. Int J Cardiol, 2022(349): 1-6.
[2]	肖涛，丘世飏，王琰. 急性冠脉综合征患者血清HsCRP和IFN-γ的检测及意义[J]. 中国现代医学杂志, 2013, 23(12): 34-37.
[3]	Ye ZL, Lu HL, Su Q, et al. Association between the level of CD4+ T lymphocyte microRNA-155 and coronary artery disease in patients with unstable angina pectoris[J]. J Geriatr Cardiol, 2018, 15(10): 611-617.
[4]	魏玮，章树业，张政, 等. 急性冠脉综合征患者共刺激分子PD-1、CD28的表达变化分析[J]. 中国现代医生, 2012, 50(18): 58-60.
[5]	Li SH, Chen WJ, Yan M, et al. Expression of coinhibitory PD-L1 on CD4+CD25+FOXP3+ regulatory t cells is elevated in patients with acute coronary syndrome[J]. Coron Artery Dis, 2015, 26(7):598-603.
[6]	Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome[J]. Clinical Immunology, 2008, 127(1): 89-97.
[7]	Ellison JM, Nohria A. An increased understanding of the association between atherosclerosis and immune checkpoint inhibitors[J]. Curr Cardiol Rep, 2023, 25(8): 879-887.
[8]	Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764.
[9]	Forteza MJ, Hervas A, de Dios E, et al. Programmed death-1 （PD-1）：a novel mechanism for understanding the acute immune deregulation in ST-segment elevation myocardial infarction[J]. Int J Cardiol, 2014, 177(1): 8-10.
[10]	Rubio-Infante N, Ramírez-Flores YA, Castillo EC, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy：a meta‐analysis[J]. Eur J Heart Fail, 2021, 23(10): 1739-1747.
[11]	Liang Y, Li L, Chen Y, et al. PD-1/PD-L1 immune checkpoints：tumor vs atherosclerotic progression[J]. Clin Chim Acta, 2021(519): 70-75.
[12]	Széles Á, Fazekas T, Váncsa S,et al. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis[J]. Cancer immunology, 2023, 72(5): 1061-1073.
[13]	Miyazaki S, Fujisue K, Yamanaga K, et al. Prognostic significance of soluble PD-L1 on cardiovascular outcomes in patients with coronary artery disease[EB/OL]. (2023-10-03)[2023-11-23]. URL
[14]	Voloshyna I, Littlefield MJ, Reiss AB. Atherosclerosis and interferon-γ：new insights and therapeutic targets[J]. Trends Cardiovasc Med, 2014, 24(1): 45-51.
[15]	Harvey EJ, Ramji DP. Interferon-γ and atherosclerosis：pro-or anti-atherogenic?[J]. Cardiovasc Res, 2005, 67(1): 11-20.
[16]	Bahrami A, Sathyapalan T, Sahebkar A. The role of interleukin-18 in the development and progression of atherosclerosis[J]. Curr Med Chem, 2021, 28(9): 1757-1774.
[17]	Hartford M, Wiklund O, Hultén LM, et al. Interleukin-18 as a predictor of future events in patients with acute coronary syndromes[J]. Arterioscler Thromb Vasc Biol, 2010, 30(10): 2039-2046.

组别	例数	年龄	男性（%）	UA	TC	LDL
对照组	20	65.70±7.39	13（65.00）	341.29±67.05	4.60±0.98	2.57±0.62
ACS组	32	69.09±14.97	19（59.38）	422.69±112.58^a	3.37±1.27^a	1.65±1.17^a
慢性冠脉疾病组	21	74.24±8.60	8（38.10）	336.50±64.62^b	3.79±1.27^a	2.30±1.08^b
检验值		2.83	3.48	7.89	6.50	5.62
P值		>0.05	>0.05	<0.01	<0.01	<0.05
组别	例数	收缩压	舒张压	Glu	TnI	CKMB
对照组	20	140.00±17.26	87.00±7.29	4.87（4.56，5.87）	/	/
ACS组	32	124.97±17.89^a	72.66±11.27^a	7.07（6.07，9.91）^a	0.36（0.16，2.32）	8.85（2.92，60.41）
慢性冠脉疾病组	21	148.62±21.33^b	72.81±14.46^a	6.96（5.32，8.44）^a	0.06（0.03，0.14）	3.37（2.72，4.61）
检验值		10.72	11.35	15.56	3.98	3.75
P值		<0.01	>0.05	<0.01	<0.05	>0.05
组别	例数	Myo	NT-proBNP	D-d	ALT	AST
对照组	20	/	/	/	19.00（14.05，44.52）	20.00（17.04，29.51）
ACS组	32	86.00（60.02，215.07）	720.50（257.38，3565.02）	275.00（0.95，843.37）	27.50（19.06，91.09）	31.50（20.06，182.38）^a
慢性冠脉疾病组	21	67.00（56.02，118.03）	322.50（152.88，747.53）	581.00（446.04，889.09）	20.00（11.53，30.58）	21.00（18.08，30.05）
检验值		1.45	2.19	4.27	3.86	6.12
P值		>0.05	>0.05	<0.05	>0.05	<0.05
组别	例数	Scr	BUN	TG	HDL	HR
对照组	20	75.00（64.03，84.08）	5.30（5.07，6.59）	1.38（0.97，1.95）	1.08（0.96，1.33）	85.00（85.05，85.07）
ACS组	32	85.50（63.83，108.37）	6.49（5.44，9.63）a	2.22（1.12，2.98）	1.43（1.13，3.04）	77.00（70.05，87.09）
慢性冠脉疾病组	21	65.00（56.06，92.03）	5.06（4.35，6.52）	1.03（0.93，2.14）	1.26（1.02，3.04）	67.00（63.55，80.53）
检验值		4.01	6.07	4.49	4.42	3.96
P值		>0.05	<0.05	>0.05	>0.05	>0.05

组别	例数	年龄	男性（%）	UA	TC	LDL
对照组	20	65.70±7.39	13（65.00）	341.29±67.05	4.60±0.98	2.57±0.62
ACS组	32	69.09±14.97	19（59.38）	422.69±112.58^a	3.37±1.27^a	1.65±1.17^a
慢性冠脉疾病组	21	74.24±8.60	8（38.10）	336.50±64.62^b	3.79±1.27^a	2.30±1.08^b
检验值		2.83	3.48	7.89	6.50	5.62
P值		>0.05	>0.05	<0.01	<0.01	<0.05
组别	例数	收缩压	舒张压	Glu	TnI	CKMB
对照组	20	140.00±17.26	87.00±7.29	4.87（4.56，5.87）	/	/
ACS组	32	124.97±17.89^a	72.66±11.27^a	7.07（6.07，9.91）^a	0.36（0.16，2.32）	8.85（2.92，60.41）
慢性冠脉疾病组	21	148.62±21.33^b	72.81±14.46^a	6.96（5.32，8.44）^a	0.06（0.03，0.14）	3.37（2.72，4.61）
检验值		10.72	11.35	15.56	3.98	3.75
P值		<0.01	>0.05	<0.01	<0.05	>0.05
组别	例数	Myo	NT-proBNP	D-d	ALT	AST
对照组	20	/	/	/	19.00（14.05，44.52）	20.00（17.04，29.51）
ACS组	32	86.00（60.02，215.07）	720.50（257.38，3565.02）	275.00（0.95，843.37）	27.50（19.06，91.09）	31.50（20.06，182.38）^a
慢性冠脉疾病组	21	67.00（56.02，118.03）	322.50（152.88，747.53）	581.00（446.04，889.09）	20.00（11.53，30.58）	21.00（18.08，30.05）
检验值		1.45	2.19	4.27	3.86	6.12
P值		>0.05	>0.05	<0.05	>0.05	<0.05
组别	例数	Scr	BUN	TG	HDL	HR
对照组	20	75.00（64.03，84.08）	5.30（5.07，6.59）	1.38（0.97，1.95）	1.08（0.96，1.33）	85.00（85.05，85.07）
ACS组	32	85.50（63.83，108.37）	6.49（5.44，9.63）a	2.22（1.12，2.98）	1.43（1.13，3.04）	77.00（70.05，87.09）
慢性冠脉疾病组	21	65.00（56.06，92.03）	5.06（4.35，6.52）	1.03（0.93，2.14）	1.26（1.02，3.04）	67.00（63.55，80.53）
检验值		4.01	6.07	4.49	4.42	3.96
P值		>0.05	<0.05	>0.05	>0.05	>0.05

组别	例数	IL-18	IFN-γ	sPD-1	sPD-L1
对照组	20	520.69（404.52，692.66）	6.83（3.54，11.67）	60.76（26.65，145.07）	14.22（7.04，20.15）
ACS组	32	735.41（615.48，909.37）^a	6.62（3.43，12.35）	188.54（101.88，863.36）^a	54.44（25.83，129.92）^a
慢性冠脉疾病组	21	734.24（596.53，953.76）^a	9.04（5.17，17.92）^ab	117.86（72.52，206.37）^ab	29.91（23.64，45.48）^ab
检验值		11.74	9.69	11.65	15.94
P值		<0.01	<0.05	<0.01	<0.01

组别	例数	IL-18	IFN-γ	sPD-1	sPD-L1
对照组	20	520.69（404.52，692.66）	6.83（3.54，11.67）	60.76（26.65，145.07）	14.22（7.04，20.15）
ACS组	32	735.41（615.48，909.37）^a	6.62（3.43，12.35）	188.54（101.88，863.36）^a	54.44（25.83，129.92）^a
慢性冠脉疾病组	21	734.24（596.53，953.76）^a	9.04（5.17，17.92）^ab	117.86（72.52，206.37）^ab	29.91（23.64，45.48）^ab
检验值		11.74	9.69	11.65	15.94
P值		<0.01	<0.05	<0.01	<0.01

Please choose a citation manager

Content to export